NOV 2 6 2004 JUNE PRADENMENT Under

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	mplete if Known	
Application Number	10/809,089	
Filing Date	03/25/04	
First Named Inventor	Andrew R. Marks	
Art Unit	1624	
Examiner Name	to be assigned	
Attarnay Docket Number	E100 144	

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D D	,	US- F 44C OCC	05-16-1995	Kaneko et al	
/B.P.	/	US- 5,416,066	00-10-1995	Kaneko, et al.	
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ ⁶
/B.P./		WO92/12148	07-23-1992	Kaneko, et al. Engli	sh Abstract O	nl
		JP4230081	08-19-1992	Kaneko, et al.		
00000000000000000	0000000000	~ }		Itsava, et al.		
						Г

Examiner Signature	/Benjamin J. Packard/	Date Considered	11/15/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

NOV 2 6 2004 US

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ABLESTITUTE for form 1449/PTO
INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/809,089

Filing Date 03/25/04

First Named Inventor Andrew R. Marks

Art Unit 1624

Examiner Name to be assigned

Attorney Docket Number 5199-144

Sheet 1 of 16

	1 au	NON PATENT LITERATURE DOCUMENTS	1				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		Alvarez et al., Late post-myocardial infarction induces a tetrodotoxin-resistant Na+ current in rat cardiomyocytes.					
		J. Mol. Cell Cardiol., 32: 1169-1179, 2000					
		Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation / flutter in a canine sterile pericarditis model.					
		J. Cardiovasc. Electrophysiol., 14: 880-884, 2003					
		Antos et al., Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A.					
		Circ. Res., 89: 997-1004, 2001					
		Barbone et al., Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure:					
		a primary role of mechanical unloading underlying reverse remodeling.					
		Circulation, 104: 670-675, 2001					

Examiner	/Beniamin J. Packard/	Date	11/15/2007
Signature	/Denjamin o. r ackaro/	Considered	11/10/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	ite for form 1449/PTO			Complete if Known			
Substitute for form 1443/F TO				Application Number	10/809,089		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	03/25/04		
STA	STATEMENT BY APPLICANT		First Named Inventor	Andrew R. Marks			
	///	4		Art Unit	1624		
	(Use as many sh	ieets as n	ecessary)	Examiner Name	to be assigned		
Sheet	2	of	16	Attorney Docket Number	5199-144		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bennett and Pentecost, The pattern of onset and spontaneous cessation of atrial fibrillation in man.	
		Circulation, 41: 981-988, 1970	
		Bennett et al., Identification and characterization of the murine FK506 binding protein (FKBP) 12.6 gene.	
		Mamm. Genome, 9: 1069-1071, 1998	
		Beuckelmann et al., Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure.	
		Circ., 85: 1046-1055, 1992	
-		Brillantes et al., Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein.	
		Cell, 77: 513-523, 1994	
		Bristow et al., Decreased catecholamine sensitivity and beta-adrenergic –receptor density in failing human hearts.	
		N. Engl. J. Med., 307: 205-211, 1982	

			1 2 13 6 15 5 5 5 7
Examiner	(D.) 1 D. () 1	Date	11/15/2007
Signature	/Benjamin J. Packard/	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	te for form 1449/PTO		ot or rose, no persons as		Complete if Known
Substitu	Substitute to form 1445/176			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	STATEMENT BY APPLICANT			First Named Inventor	Andrew R. Marks
	NFORMATION DISCLOSUR STATEMENT BY APPLICAN (Use as many sheets as necessary)		Art Unit	1624	
	(Use as many sne	eets as n	ecessary)	Examiner Name	to be assigned
Sheet	3	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Burashnikov and Antzelevitch, Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early	
		afterdepolarization-induced triggered activity.	
		Circulation, 107: 2355-2360, 2003	
		Cameron et al., FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this	
		FK506-like domain.	
		J. Biol. Chem., 272: 27582-27588, 1997	
		Chen et al., Mechanism of TGFbeta receptor inhibition by FKBP12.	
		EMBO J., 16: 3866-3876, 1997	
	-	Chidsey et al., Augmentation of plasma norepinephrine response to exercise in patients with congestive heart failure.	
		N. Engl. J. Med., 267: 650, 1962	

Examiner		Date	
Signature	/Benjamin J. Packard/	Considered	11/15/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	te for form 1449/PTO				Complete if Known
Jubstitu	te to to to the table to			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she	oto ao a	ooossand	Art Unit	1624
	(Ose as many sne	ets as II	ecessary)	Examiner Name	to be assigned
Sheet	4	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chugh et al., Epidemiology and natural history of atrial fibrillation: clinical implications.	
		J. Am. Coll. Cardiol., 37: 371-378, 2001	
		Cranefield, P.F., Action potentials, afterpotentials, and arrhythmias.	
		Circ. Res., 41: 415-423, 1977	
		Daoud et al., Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.	
		Circulation, 96: 1542-1550, 1997	
		Dun et al., Chronic atrial fibrillation does not further decrease outward currents. It increases them.	
		Am. J. Physiol. Heart Circ. Physiol., 285: H1378-1384, 2003	
		Eichhorn and Bristow, Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure.	
		Circulation, 94: 2285-2296, 1996	

Examiner	m - ' - ' - ' - ' - ' - ' - ' - ' - ' -	Date	
Signature	/Benjamin J. Packard/	Considered	11/15/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/P1	ſΩ		Complete if Known		
- Jupatio	te 101 101111 144071 1			Application Number	10/809,089	
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	03/25/04	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Andrew R. Marks	
	(11	-44		Art Unit	1624	
	(Use as many sheets as necessary)			Examiner Name	to be assigned	
Sheet	5	of	16	Attorney Docket Number	5199-144	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Elvan et al., Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling.	
		Circulation, 94: 2953-2960, 1996	
		Fabiato, A., Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum.	
		Am. J. Physiol., 245: C1-C14, 1983	
		Falk, R.H., Atrial fibrillation.	
		N. Engl. J. Med., 344: 1067-1078, 2001	
		Fozzard, H.A., Afterdepolarizations and triggered activity.	
		Basic Res. Cardiol., 87: 105-113, 1992	
		Gaspo et al., Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model.	
		Circulation, 96: 4027-4035, 1997	

Examiner	/m ' '	Date	11/15/2007	ı
Signature	/Benjamin J. Packard/	Considered	11/10/2007	ı

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

					Complete if Known
Substitu	le 10/10/11/1449/110			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	DRMATION DISCLOSURE TEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1624	
	(Use as many sne	ets as n	ecessary)	Examiner Name	to be assigned
Sheet	6	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gillo et al., Calcium entry during induced differentiation in murine erythroleukemia cells.	
		Blood, 81: 783-792, 1993	
		Goette et al., Electrical remodeling in atrial fibrillation: time course and mechanisms.	
		Circulation, 94: 2968-2974, 1996	
		Gomez et al., Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure.	
_ :-		Science, 276: 800-806, 1997	
		Gwathmey et al., Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.	
		Circ. Res., 61: 70-76, 1987	
		Hain et al., Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle.	
		J. Biol. Chem., 270: 2074-2081, 1995	

Examiner	(5) ' ' (5) (4)	Date	11/15/2007
	/Beniamin J. Packard/		
Signature	, conjuntition i dollara	Considered	
Dignature		Constacted	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	te for form 1449/PTO				Complete if Known
Substitu	te 10/10/11/1443/1110			Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she	ote se s	ocassani)	Art Unit	1624
	(Ose as many sne	ets as n	ecessary)	Examiner Name	to be assigned
Sheet	7	of	16	Attorney Docket Number	5199-144

<u> </u>		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Hara et al., Steady-state and nonsteady-state action potentials in fibrillating canine atrium: abnormal rate adaptation and its possible mechanisms.	
		Cardiovasc. Res., 42: 455-469, 1999	
· · · · · · · · · · · · · · · · · · ·		Jayaraman et al., FK506 binding protein associated with the calcium release channel (ryanodine receptor).	
		J. Biol. Chem., 267: 9474-9477, 1992	
		Jayaraman et al., Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation.	
	-	Science, 272: 1492-1494, 1996	
		Kaftan et al., Effects of rapamycin on ryanodine receptor / Ca (2+)-release channels from cardiac muscle.	
-		Circ. Res., 78: 990-997, 1996	
		Kneller et al., Remodeling of Ca2+ - handling by atrial tachycardia: evidence for a role in loss of rate-adaptation.	
		Cardiovasc. Res., 54: 416-426, 2002	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature		Considered	11/15/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

and the state of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PTO			Complete if Known		
Substitu	te 101 101111 1445/1 10			Application Number	10/809,089	
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks	
	//			Art Unit	1624	
	(Use as many she	ets as n	lecessary)	Examiner Name	to be assigned	
Sheet	8	of	16	Attorney Docket Number	5199-144	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kohno et al., A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure.	
		Am. J. Physiol. Heart Circ. Physiol., 14:14, 2002	
		Kumagai et al., Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation / flutter in a canine sterile pericarditis model.	
		J. Cardiovasc. Electrophysiol., 14: 880-884, 2003	
		Laitinen et al., Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia.	
		Circulation, 103: 485-490, 2001	
		Leenhardt et al., Catecholaminergic polymorphic ventricular.tachycardia in children: a 7-year follow-up of 21 patients.	
		Circulation, 91: 1512-1519, 1995	
		Leistad et al., Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644.	
		Circulation, 93: 1747-1754, 1996	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature	,	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Cubatita	Substitute for form 1449/PTO			Complete if Known		
Substitu	ite 101 101111 1445/F10			Application Number	10/809,089	
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/25/04	
STA	ATEMENT 8	BY A	PPLICANT	First Named Inventor	Andrew R. Marks	
	///	4		Art Unit	1624	
(Use as many sheets as necessary)				Examiner Name	to be assigned	
Sheet	9	of	16	Attorney Docket Number	5199-144	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Levy et al., Long-term trends in the incidence of and survival with heart failure.	
		N. Engl. J. Med., 347: 1397-1402, 2002	
		Marban et al., Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle.	
		J. Clin. Invest., 78: 1185-1192, 1986	
		Marks, A.R., Cellular functions of immunophilins.	
		Physiol. Rev., 76: 631-649, 1996	
		Marks, A.R., Cardiac intracellular calcium release channels: role in heart failure.	
		Circ. Res., 87: 8-11, 2000	
		Marks et al., Progression of heart failure: is protein kinase a hyperphosphorylation of the ryanodine receptor a contributing factor?	
		Circulation, 105: 272-275, 2002	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature	,	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	te for form 1449/PTO		• •	e required to respond to a collection	Complete if Known		
Substitut	te 101 10/111 1779/1 10			Application Number	10/809,089		
INFO	ORMATION	DIS	CLOSURE	Filing Date	03/25/04		
STA	STATEMENT BY APPLICANT			First Named Inventor	Andrew R. Marks		
	(Use as many she	oto oo n	neoceand.	Art Unit	1624		
	(Use as many sne	els as II	ecessary)	Examiner Name	to be assigned		
Sheet	10	of	16	Attorney Docket Number	5199-144		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Marx et al., Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors).	
		Science, 281: 818-821, 1998	
		Marx et al., PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.	
		Cell, 101: 365-376, 2000	
		Mohler et al., Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.	
		Nature, 421: 634-639, 2003	
		Morillo et al., Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation.	
		Circulation, 91: 1588-1595, 1995	
		Nabauer et al., Regulation of calcium release is gated by calcium current, not gating charge, in cardiac myocytes.	
		Science, 244: 800-803, 1989	
	l		

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	STATEMENT BY APP			Complete if Known	
Substitu	ite ioi iomi 1449/F1O			Application Number	10/809,089
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/25/04
STA	ATEMENT I	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	ORMATION DISCLOSUR ATEMENT BY APPLICAN (Use as many sheets as necessary)			Art Unit	1624
	(Use as many sn	eets as n	ecessary)	Examiner Name	to be assigned
Sheet	11	of	16	Attorney Docket Number	5199-144

		NON DATENT LITED ATUDE DOCUMENTS	
Examiner Initials*	Cite No. ¹	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ono et al., Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca2+ release in heart failure.	
		Cardiovasc. Res., 48: 323-331, 2000	
		Priori et al., Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.	
		Circulation, 106: 69-74, 2002	
		Priori et al., Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia.	
		Circulation, 103: 196-200, 2001	
		Ramirez et al., Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling.	
		Am. J. Physiol. Heart Circ. Physiol., 279: H1767-1785, 2000	
		Reiken et al., Beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure.	
		Circulation, 104: 2843-2848, 2001	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature	,	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

**Commissioner For Patents P.O. Box 1450, Alexandria VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	Under the Paperwork Reduction Act of 1995, no persons substitute for form 1449/PTO NFORMATION DISCLOSURE				Complete if Known
Jupania	te 10/10/11/ 1445// 10			Application Number	10/809,089
INF		CLOSURE	Filing Date	03/25/04	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(llee ee many she			Art Unit	1624
	(USB as many sne	ets as n	ecessary)	Examiner Name	to be assigned
Sheet	12	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Reiken et al., Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure.	
		Circulation, 107: 2459-2466, 2003	
		Reiken et al., PKA phosphorylation dissociates FKBP12 from the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation	
		in heart failure.	
		J. Cell Biol., 160: 919-928, 2003	
		Rensma et al., Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.	
		Circ. Res., 62: 395-410, 1988	
		Semsarian et al., The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.	
		J. Clin. Invest., 109: 1013-1020, 2002	

Examiner	/Beniamin J. Packard/	Date	11/15/2007
Signature	/Benjamin J. Packard/	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered, Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	bstitute for form 1449/PTO NFORMATION DISCLOSURE TATEMENT BY APPLICANT		Complete if Known		
Juosiitu	Substitute for form 17401 10		Application Number	10/809,089	
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she			Art Unit	1624
	(Ose as many sne	eis as n	ecessary)	Examiner Name	to be assigned
Sheet	13	of	16	Attorney Docket Number	5199-144

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	Song and Belardinelli, ATP promotes development of afterdepolarizations and triggered activity in cardiac myocytes.	
	Am. J. Physiol., 267: H2005-2011, 1994	
	Sun et al., Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia.	
	Circulation, 98: 719-727, 1998	
	Swan et al., Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts.	
	J. Am. Coll. Cardiol., 34: 2035-2042, 1999	
	Tieleman et al., Verapamil reduces tachycardia-induced electrical remodeling of the atrial.	
	Circulation, 95: 1945-1953, 1997	
	Timmermans et al., Immediate reinitiation of atrial fibrillation following internal atrial defibrillation.	
	J. Cardiovasc. Electrophysiol., 9: 122-128, 1998	
		Cite No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Song and Belardinelli, ATP promotes development of afterdepolarizations and triggered activity in cardiac myocytes. Am. J. Physiol., 267: H2005-2011, 1994 Sun et al., Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation, 98: 719-727, 1998 Swan et al., Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J. Am. Coll. Cardiol., 34: 2035-2042, 1999 Tieleman et al., Verapamil reduces tachycardia-induced electrical remodeling of the atrial. Circulation, 95: 1945-1953, 1997 Timmermans et al., Immediate reinitiation of atrial fibrillation following internal atrial defibrillation.

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO				Complete if Known
Substitu				Application Number	10/809,089
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	NFORMATION DISCLOSUF STATEMENT BY APPLICAN (Use as many sheets as necessary)		Art Unit	1624	
	(Use as many sne	eets as n	ecessary)	Examiner Name	to be assigned
Sheet	14	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Valdivia et al., Rapid adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phosphorylation.	
		Science, 267: 1997-2000, 1995	
		Wang et al., Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs.	
		Am. J. Physiol., 271: H148-158, 1996	
		Wehrens et al., FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death.	
		Cell, 113: 829-840, 2003	
		Wellens et al., Atrioverter: an implantable device for the treatment of atrial fibrillation.	
		Circulation, 98: 1651-1656, 1998	
		Wijffel et al., Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats.	
	·	Circulation, 92:1954-1968, 1995	

			r=
Examiner	/Panjamin Dackard/	Date	11/15/2007
Signature	/Benjamin J. Packard/	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO				Complete if Known
Jubstitu	te for form 1443/F10			Application Number	10/809,089
INF	ORMATION	I DIS	CLOSURE	Filing Date	03/25/04
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Andrew R. Marks
	(Use as many she	noto aa		Art Unit	1624
	(USE as many sne	eets as n	ecessary)	Examiner Name	to be assigned
Sheet	15	of	16	Attorney Docket Number	5199-144

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wit and Rosen, Pathophysiologic mechanisms of cardiac arrhythmias.	
		Am. Heart J., 106: 798-811, 1983	
		Yamamoto et al., Abnormal Ca2+ release from cardiac sarcoplasmic reticulum in tachycardia-induced heart failure.	i,
		Cardiovasc. Res., 44: 146-155, 1999	
		Yano et al., Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca2+ leak through ryanodine receptor in heart failure.	
		Circulation, 102: 2131-2136, 2000	
	- - - -	Yano et al., FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure.	
		Circulation, 107: 477-484, 2003	
		Yu et al., Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.	
		Circulation, 97: 2331-2337, 1998	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature		Considered	11, 13, 23

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
- Substitute for form 1445/1/5				Application Number	10/809,089
INF	ORMATION	DIS	CLOSURE	Filing Date	03/25/04
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Andrew R. Marks
				Art Unit	1624
(Use as many sheets as necessary)			ecessary)	Examiner Name	to be assigned
Sheet	16	of	16	Attorney Docket Number	5199-144

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Yue et al., Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation.	
		Circ. Res., 81: 512-525, 1997	

Examiner	/Benjamin J. Packard/	Date	11/15/2007
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.